TEVA — TEVA PHARMACEUTICAL INDUSTRIES LTD

—
NYSE · Health Care · Pharmaceuticals · CIK 818686 · Israel
Last close
$42.62
Market Cap
$49.73B
52W High
$44.57
52W Low
$24.01
ADV30
7,318,329
Next earnings
2027-01-27

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 — — — — — — —
Jun 2026 4,142,000,000 2,153,000,000 149,000,000 -576,000,000 39,857,000,000 3,655,000,000 32,100,000,000
Mar 2026 3,981,000,000 1,972,000,000 759,000,000 369,000,000 40,040,000,000 3,741,000,000 31,808,000,000
Dec 2025 4,711,000,000 2,656,000,000 1,269,000,000 480,000,000 40,748,000,000 3,556,000,000 32,834,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$1,770,000,000
Investing CF
$114,000,000
Financing CF
$57,000,000
CapEx
$-580,000,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.43
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-13,736,000,000
Inventory
$3,173,000,000
Receivables
$3,837,000,000
ST Investments
—
EBIT TTM
$1,224,000,000
Pretax Income TTM
$362,000,000
Interest Exp TTM
$862,000,000
Analysts
14

Yahoo Snapshot (yfinance, live)

Total Revenue
$17,230,000,128
EBITDA
$4,405,000,192
Free Cash Flow
$1,492,000,000
Enterprise Value
$62,636,490,752
Total Cash
$4,084,999,936
Total Debt
$16,997,999,616
Shares Out
1,166,826,784
Trailing EPS
$0.43
Book Value
$6.84
ROE
6.7%
ROA
5.4%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 17,257,000,000 3,952,000,000 1,410,000,000 40,748,000,000 32,834,000,000 7,910,000,000 1,649,000,000
Dec 2024 16,544,000,000 3,364,000,000 -1,639,000,000 39,326,000,000 33,606,000,000 5,373,000,000 1,247,000,000
Dec 2023 15,845,000,000 3,194,000,000 -559,000,000 43,479,000,000 35,353,000,000 7,506,000,000 1,368,000,000
Dec 2022 14,925,000,000 2,690,000,000 -2,446,000,000 44,011,000,000 35,413,000,000 7,804,000,000 1,590,000,000

TTM Snapshot

Revenues TTM
$17,315,000,000
NetIncome TTM
$707,000,000
OpCashFlow TTM
—
Assets (Latest)
$39,857,000,000
Forward EPS
$3.12

Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $32.00 · spot: $42.23 · call volume: 2,118 · put volume: 791
Expected Move to 2026-12-18: ±$3.05 (7.22%) — implied range $39.18 – $45.28 · ATM straddle on $42.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ONC BeOne Medicines Ltd. $43.55B $413.26 —
TAK TAKEDA PHARMACEUTICAL CO LTD $69.11B $21.64 —
ZTS Zoetis Inc. $33.92B $83.48 —
GMAB GENMAB A/S $31.95B $51.96 —
RPRX Royalty Pharma plc $30.58B $68.68 —

News headlines (Yahoo Finance, 1h cache)

Teva Announces R&D Leadership Transition; Eric Hughes to Depart the Company
2026-11-18 22:00 · Yahoo
U.S. FDA Approves IGALMI® as First At-Home Acute Treatment for Agitation Associated with Schizophrenia, Schizoaffective Disorder, or Bipolar I or II Disorder in Adults
2026-11-16 13:00 · Yahoo
AJOVY® Formally Included in China's National Reimbursement Drug List 2026
2026-11-14 13:51 · Yahoo
Teva Pharmaceutical Industries (TEVA) Holds First R&D Day With New Pipeline Milestones
2026-11-12 10:14 · Yahoo
Teva Pharmaceutical Industries (TEVA) Earnings Put Its Turnaround Valuation Back In Focus
2026-11-12 05:13 · Yahoo
Teva Pharmaceutical Industries Targets Up to $7 Billion in Innovative Drug Revenue by 2030
2026-11-11 21:12 · Yahoo
Sector Update: Healthcare Stocks Softer in Afternoon Trading
2026-11-11 18:29 · Yahoo
Teva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6–7 Billion in Innovative Medicines Revenue by 2030
2026-11-11 12:30 · Yahoo
FDA Decision Watch: Summit’s Lung Cancer Drug, Cytokinetics’ Heart Therapy And Teva’s Igalmi In Spotlight This Week
2026-11-09 10:23 · Yahoo
Teva's 3 Key Branded Drugs Grew Sales 33% Last Quarter. Is This Turnaround Stock a Buy Right Now?
2026-11-06 14:08 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.